Park Medi World Limited Authorizes CFO for Regulatory Disclosure Responsibilities

1 min read     Updated on 28 Jan 2026, 12:39 PM
scanx
Reviewed by
Ashish TScanX News Team
Overview

Park Medi World Limited has authorized Chief Financial Officer Rajesh Sharma as Key Managerial Personnel for determining materiality and making regulatory disclosures under SEBI Listing Regulations. The formal designation ensures compliance with Regulation 30(5) requirements and has been communicated to BSE and NSE. This authorization strengthens the company's governance framework and ensures streamlined regulatory compliance processes.

31129748

*this image is generated using AI for illustrative purposes only.

Park Medi World Limited has announced the formal authorization of its Chief Financial Officer to handle regulatory disclosures and materiality determinations under SEBI regulations. The healthcare company has designated Mr. Rajesh Sharma, CFO, as the Key Managerial Personnel responsible for these critical compliance functions.

Regulatory Compliance Framework

The authorization comes in compliance with Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Under this framework, the Board of Directors has identified and authorized specific personnel to determine the materiality of events or information and make necessary disclosures to stock exchanges.

Key Personnel Authorization Details

The company has provided comprehensive contact information for the authorized personnel to ensure seamless communication with regulatory bodies and stakeholders:

Parameter: Details
Authorized Personnel: Mr. Rajesh Sharma
Designation: Chief Financial Officer
Contact Number: +91 124 696 00 00
Email: director.finance@parkhospital.in

Communication and Transparency

Park Medi World Limited has formally communicated this authorization to both major stock exchanges where its shares are listed. The company trades on BSE with scrip code 544645 and on NSE under the symbol PARKHOSPS. Additionally, the disclosure has been made available on the company's official website at parkhospital.in, ensuring transparency and easy access for all stakeholders.

Corporate Governance Enhancement

This formal authorization represents a structured approach to corporate governance and regulatory compliance. By designating specific Key Managerial Personnel for materiality determination and disclosure responsibilities, the company ensures streamlined decision-making processes and timely communication of material information to the market. The appointment strengthens the company's compliance framework and demonstrates its commitment to maintaining high standards of corporate governance.

like18
dislike

Park Medi World Limited Schedules Board Meeting on January 28, 2026 for Q3FY26 Financial Results

1 min read     Updated on 22 Jan 2026, 04:16 PM
scanx
Reviewed by
Naman SScanX News Team
Overview

Park Medi World Limited has scheduled a board meeting for January 28, 2026, to consider and approve Q3FY26 unaudited financial results for the quarter and nine months ended December 31, 2025. The company has notified BSE and NSE in compliance with SEBI Regulation 29. Trading window restrictions are in effect from December 31, 2025, until 48 hours after results publication, as per the company's insider trading prevention code.

30624367

*this image is generated using AI for illustrative purposes only.

Park Medi World Limited has announced a board meeting scheduled for January 28, 2026, to review and approve its unaudited financial results for the third quarter of fiscal year 2026. The company formally notified both major stock exchanges about this important corporate development through official communications dated January 22, 2026.

Board Meeting Details

The meeting agenda focuses on considering and approving both standalone and consolidated unaudited financial results for specific reporting periods. The company has structured this review to cover comprehensive financial performance across different operational segments.

Meeting Parameter: Details
Date: January 28, 2026
Purpose: Q3FY26 unaudited financial results
Reporting Period: Quarter ended December 31, 2025
Extended Period: Nine months ended December 31, 2025
Result Type: Standalone and consolidated

Regulatory Compliance

Park Medi World Limited has fulfilled its disclosure obligations under Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company submitted formal intimations to both BSE Limited at P.J. Tower, Dalal Street, Fort, Mumbai, and National Stock Exchange of India Limited at Exchange Plaza, Bandra-Kurla Complex, Mumbai.

Trading Window Restrictions

In accordance with the company's Code of Conduct for Prevention of Insider Trading, specific trading restrictions have been implemented. The trading window for Park Medi World Limited securities will remain closed from Wednesday, December 31, 2025, continuing until 48 hours after the financial results are made public.

Trading Window Details: Information
Closure Start: December 31, 2025
Closure End: 48 hours post-results publication
Applicable Securities: All company securities
Compliance Framework: Insider Trading Prevention Code

Corporate Communication

The official communication was signed by Abhishek Kapoor, serving as Company Secretary & Compliance Officer. The digital signature was executed on January 22, 2026, at 15:27:24 +05'30', ensuring proper authentication and regulatory compliance for this material disclosure.

like20
dislike

More News on Park Medi World